Not medical advice. This website is not medical advice, a diagnosis, a match to a trial, or a recommendation to join a study. Listings are plain-English rewrites of public ClinicalTrials.gov records. Whether a site is still enrolling, and whether you qualify, can only be confirmed by the study team and your clinician. Source registry: ClinicalTrials.gov. Editorial rules: methodology.
RecruitingNot a traditional drug phaseinterventionalRules rewrite
Not a traditional drug phase: Fall Prevention for Alzheimer's Disease and Related Dementia
Persons living with dementia (PLWD) are at significantly increased risk for falls, which are the leading cause of emergency department (ED) visits in this population and contribute to serious injuries, functional decline, and caregiver burden. GAPcareAD is an ED-initiated, caregiver-inclusive intervention designed to address fall risk at the point of care.
This study does not use the classic phase 1–4 drug ladder. It may be a device, a behavior program, a surgery timing study, or an early feasibility test.
Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
What the registry says happens
If you join, the listed intervention(s) are Fall Prevention. The registry lists allocation as randomized. Persons living with dementia (PLWD) are at significantly increased risk for falls, which are the leading cause of emergency department (ED) visits in this population and contribute to serious injuries, functional decline, and caregiver burden.
They plan to enroll about 700 people at 2 sites. Taking part typically means study visits and measurements plus check-ins.
Official title (unrewritten)
GAPcareAD: A Brief Emergency Department Intervention to Address Post-Fall Care Needs of Persons Living With Dementia and Care Partners
Interventions: Fall Prevention
Primary outcome (registry wording): Effect of intervention
Who it is for (from inclusion criteria)
Ages 65 Years to any
Community-dwelling adult (living at home or assisted living) 65 years-old or older presenting to ED after a fall within the last seven days
Fall not due to syncope or external force (i.e., struck by car,assault, intoxication)
Fall not due to serious illness (i.e., stroke, acute myocardial infarction)
Patients have an identified caregiver
Patient must have known ADRD or score ≥2 on the AD8 Dementia Interview
Anticipated to be discharged to home/assisted living/rehabilitation at the time of consent (i.e. not admitted)
The patient and/or caregiver have a reliable phone number where they can be reached throughout the intervention
Who the registry excludes
Living in a nursing home
Patients are admitted to the hospital
Patients who have advanced cancer and/or are in hospice
Patients have presence of injuries that prevent mobilization (i.e. pelvic or lower extremity fractures)
Contact
No central phone on the registry card. Use the official listing to reach a site.
Sites listed on ClinicalTrials.gov
2 listed
UCH University of Colorado — Aurora, Colorado (recruiting)
Washington University — St Louis, Missouri (recruiting)
The specific aims of the study are: Primary: To determine the presence and regional distribution of microglial activation, as assessed by Fluorine-18 (18F) labeled "Peripheral Benzodiazepine Receptor 06" (PBR06) -PET, in subjects with active Relapsing Remitting Multiple Sclerosis (RRMS), Secondary Progressive Multiple Sclerosis (SPMS), and Alzheimer's Disease (AD) as compared to healthy controls Secondary: 1. To assess the relationship between microglial activation and clinical variables including disease severity and comorbidities (such as pain, fatigue and/or depression), as well as clinical MRI findings (such as lesions and atrophy) 2.
This study will look at whether nabilone is an effective treatment for agitation in Alzheimer's disease (AD) patients. Agitation is highly prevalent in patients with AD and is one of the most distressing and challenging-to-treat symptoms.
The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.
What phase is NCT07563270?
Not a traditional drug phase. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
Can PlainTrials tell me if I qualify for NCT07563270?
No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.